HYPERMED IMAGING, INC.

HyperMed is developing hyperspectral imaging for medical applications. The technology, originally developed for military surveillance, provides an advanced form of spectroscopy that provides a two-dimensional tissue oxygenation map. The company’s first product, OxyVu, was developed for the US research market and subsequently received FDA 510(k) approval for medical diagnostic applications where the measurement of microvasculature perfusion can assist physicians with patient care. Multiple published studies have demonstrated the clinical utility of OxyVu for the diagnostic assessment of wound healing, diabetic foot ulcers, and amputation planning. The market opportunity for the clinical diagnostic applications for hyperspectral imaging represent a multi-billion market.